Aligned Genetics Inc
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genet… Read more
Aligned Genetics Inc (238120) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.058x
Based on the latest financial reports, Aligned Genetics Inc (238120) has a cash flow conversion efficiency ratio of -0.058x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.04 Billion) by net assets (₩35.50 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aligned Genetics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Aligned Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aligned Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aligned Genetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SaverOne 2014 Ltd. American Depositary Shares
NASDAQ:SVRE
|
-0.914x |
|
P-Two Industries
TWO:6158
|
0.061x |
|
BENAKAT INTEGRA (J9B.SG)
STU:J9B
|
-0.048x |
|
Passage Bio Inc
NASDAQ:PASG
|
-0.156x |
|
West Coast Silver Ltd
AU:WCE
|
-3.405x |
|
Nusasiri Public Company Limited
BK:NUSA
|
0.001x |
|
Bayfirst Financial Corp
NASDAQ:BAFN
|
0.540x |
|
Enjoei S.A
SA:ENJU3
|
0.112x |
Annual Cash Flow Conversion Efficiency for Aligned Genetics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Aligned Genetics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩35.49 Billion | ₩3.07 Billion | 0.086x | -5.07% |
| 2023-12-31 | ₩31.31 Billion | ₩2.85 Billion | 0.091x | +18.10% |
| 2022-12-31 | ₩28.85 Billion | ₩2.22 Billion | 0.077x | +1429.28% |
| 2021-12-31 | ₩26.99 Billion | ₩135.97 Million | 0.005x | +203.10% |
| 2020-12-31 | ₩21.46 Billion | ₩35.67 Million | 0.002x | -94.71% |
| 2019-12-31 | ₩20.97 Billion | ₩659.29 Million | 0.031x | +137.58% |
| 2018-12-31 | ₩20.89 Billion | ₩-1.75 Billion | -0.084x | -116.08% |
| 2017-12-31 | ₩22.64 Billion | ₩-876.75 Million | -0.039x | +17.86% |
| 2016-12-31 | ₩24.18 Billion | ₩-1.14 Billion | -0.047x | +18.73% |
| 2015-12-31 | ₩6.06 Billion | ₩-351.72 Million | -0.058x | -- |